Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Aspira Women's Health Inc. (AWHL) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5184 stocks scored
Rank correlation · 90D -22.0% Spearman, 357 dates
Market Cap $11M small-cap · #12 of 17 peers
Summary

Aspira Women's Health Inc. (AWHL) stock forecast summary

On Oct. 16, 2026, AWHL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.

Aspira Women's Health Inc. is a small-cap company with a market capitalization of $11M. It ranks number 12 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.

For AWHL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -22.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, AWHL included.

Follow AWHL free
Price

AWHL price chart and AI forecast

AWHL
Cross-section · 2026-10-16

How AWHL ranks among 5184 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Aspira Women's Health Inc. (AWHL) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.

Valuation & Market

MetricAWHLIndustry medianRank
Market Cap $11M $380M 12/17
EPS $-0.14 – –

Profitability & Margins

MetricAWHLIndustry medianRank
Operating Margin -3271.8% -74.4% 12/14
EBT Margin -2003.5% -62.4% 11/14

Financial Health

MetricAWHLIndustry medianRank
Current Ratio 0.52x 2.63x 15/16
Quick Ratio 0.48x 1.98x 10/10
Interest Coverage 8.1x -0.2x 5/14
Working Capital -$3M $20M 14/16

Cash Flow

MetricAWHLIndustry medianRank
Operating Cash Flow -$5M -$6M 7/16

Operational Efficiency

MetricAWHLIndustry medianRank
Inventory Turnover 15.6x 4.1x 1/10
Days Inventory 23 days 88 days 10/10
Payables Period 279 days 57 days 2/10

Income Statement

MetricAWHLIndustry medianRank
Operating Income -$7M -$12M 7/15
R&D Expense $3M $19M 11/16
SG&A Expense $10M $28M 10/12
Cost of Goods Sold $4M $140M 9/10

Dividend & Shareholder Information

MetricAWHLIndustry medianRank
Shares Outstanding 47M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$3M
Cash & Short-term Investments$480K
Accounts Receivable$1M
Inventory$230K
Total Liabilities$12M
Short-term Debt$3M
Quarterly Financial Reports

AWHL quarterly financials and insider trading

Industry Peers · In Vitro & In Vivo Diagnostic Substances

Aspira Women's Health Inc. (AWHL) industry peers

Companies classified under the same SEC industry code as Aspira Women's Health Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
AWHL Aspira Women's Health Inc. ▶ $11M – –
IDXX Idexx Laboratories Inc /De ▼ $44.15B 39.4x 27.4x
LNTH Lantheus Holdings, Inc. ▼ $6.51B 23.9x 5.0x
NEOG Neogen Corp ▲ $2.58B – 1.2x
CLDX Celldex Therapeutics, Inc. ▲ $2.16B – 3.0x
NTLA Intellia Therapeutics, Inc. ▲ $1.60B – 2.2x
QDEL Quidelortho Corp ▶ $885M – 0.5x
ACHV Achieve Life Sciences, Inc. ▲ $657M – –
MYGN Myriad Genetics Inc ▲ $381M – 1.3x
TKNO Alpha Teknova, Inc. ▲ $380M – 6.1x
IMDX Insight Molecular Diagnostics Inc. ▲ $98M – –
ICCC Immucell Corp /De/ ▶ $98M 537.6x 3.1x
BMRA Biomerica Inc ▲ $9M – 2.3x
TRIB Trinity Biotech Plc ▼ $7M – –
CDIO Cardio Diagnostics Holdings, Inc. ▲ $5M – 0.7x
QCLS Q/C Technologies, Inc. ▼ $4M – 0.3x
VNRX Volitionrx Ltd ▼ $2M – –

Where AWHL sits on the market map

Life Sciences · In Vitro & In Vivo Diagnostic Substances
Explore the map →
News

Aspira Women's Health Inc. (AWHL) stock news

Loading...

FAQ

Aspira Women's Health Inc. (AWHL) stock forecast FAQ

What is the Aspira Women's Health Inc. (AWHL) stock forecast?

On Oct. 16, 2026, AWHL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.

How accurate are Aspira Women's Health Inc. stock predictions?

For AWHL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -22.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Aspira Women's Health Inc. forecasts updated?

Aspira Women's Health Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Aspira Women's Health Inc.'s industry peers?

17 issuers in our coverage, AWHL included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.